Single-chain basiliximab antibody-transferrin fusion protein for enhanced efficacy and indications

Abstract

The efficacy and indication of basiliximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

Dependencies are inferred from the claim text.